Notably, the mRNA level of GOT2 was strongly associated with poor overall survival and disease‐free survival in BC patients in the BreastMark Database cohort (Madden et al., 2013) (P < 0.001, Kaplan–Meier survival analysis and log‐rank test, Fig. 6D) and KMplot database cohort (Gyorffy et al., 2010) (P < 0.001 for OS and P = 0.034 for DFS, Kaplan–Meier survival analysis and log‐rank test, Fig. S6B), and was also correlated with overall survival of BC patients in the TCGA cohort analyzed by the Human Protein Atlas (https://www.proteinatlas.org/, P = 0.015, Fig. S6C). The gene discussed is GOT2; the disease is breast cancer.